{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:41:11Z","timestamp":1769604071777,"version":"3.49.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgery"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.surg.2020.05.039","type":"journal-article","created":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T18:00:22Z","timestamp":1595354422000},"page":"138-144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Molecular genomic profiling of adrenocortical cancers in clinical practice"],"prefix":"10.1016","volume":"169","author":[{"given":"Sourat","family":"Darabi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.","family":"Braxton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Burton L.","family":"Eisenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Demeure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.surg.2020.05.039_bib1","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/s00268-005-0329-x","article-title":"Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress?","volume":"30","author":"Kebebew","year":"2006","journal-title":"World J Surg"},{"key":"10.1016\/j.surg.2020.05.039_bib2","unstructured":"Adam MP, Ardinger HH, Pagon RA, et\u00a0al, eds. GeneReviews. Seattle (WA): University of Washington, Seattle; 1993-2020. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1116\/."},{"key":"10.1016\/j.surg.2020.05.039_bib3","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1002\/cncr.23886","article-title":"Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors","volume":"113","author":"Bilimoria","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.surg.2020.05.039_bib4","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1210\/er.2013-1029","article-title":"Adrenocortical carcinoma","volume":"35","author":"Else","year":"2014","journal-title":"Endocr Rev"},{"key":"10.1016\/j.surg.2020.05.039_bib5","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.surg.2020.05.039_bib6","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ccell.2016.04.002","article-title":"Comprehensive pan-genomic characterization of adrenocortical carcinoma","volume":"29","author":"Zheng","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.surg.2020.05.039_bib7","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.surg.2020.05.039_bib8","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"key":"10.1016\/j.surg.2020.05.039_bib9","doi-asserted-by":"crossref","first-page":"23312","DOI":"10.18632\/oncotarget.8196","article-title":"Genomic landscape of DNA repair genes in cancer","volume":"7","author":"Chae","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.surg.2020.05.039_bib10","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1677\/erc.1.01025","article-title":"Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial","volume":"12","author":"Berruti","year":"2005","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.surg.2020.05.039_bib11","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S1470-2045(15)70081-1","article-title":"Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study","volume":"16","author":"Fassnacht","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.surg.2020.05.039_bib12","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1038\/s41467-018-06366-z","article-title":"Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors","volume":"9","author":"Gara","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.surg.2020.05.039_bib13","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.celrep.2019.07.001","article-title":"Integrated analysis of TP53 gene and\u00a0pathway alterations in the cancer genome atlas","volume":"28","author":"Donehower","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.surg.2020.05.039_bib14","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/onc.2017.344","article-title":"Contrasting effects of an Mdm2 functional\u00a0polymorphism on tumor phenotypes","volume":"37","author":"Ortiz","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.surg.2020.05.039_bib15","series-title":"GeneReviews","article-title":"Li-Fraumeni syndrome","author":"Schneider","year":"2013"},{"key":"10.1016\/j.surg.2020.05.039_bib16","doi-asserted-by":"crossref","first-page":"8610","DOI":"10.1038\/s41598-018-26799-2","article-title":"Comprehensive analysis of CTNNB1 in adrenocortical carcinomas: Identification of novel mutations and correlation to survival","volume":"8","author":"Maharjan","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.surg.2020.05.039_bib17","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.dnarep.2018.04.004","article-title":"Advances in therapeutic targeting of the DNA damage response in cancer","volume":"66-7","author":"Desai","year":"2018","journal-title":"DNA Repair (Amst)"},{"key":"10.1016\/j.surg.2020.05.039_bib18","first-page":"629388","article-title":"Overview: FDA approval of olaparib maintenance for BRCA-mutated","volume":"33","author":"Saleh","year":"2019","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.surg.2020.05.039_bib19","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1093\/annonc\/mdz134","article-title":"Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer","volume":"30","author":"Schrock","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.surg.2020.05.039_bib20","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3389\/fphar.2019.00673","article-title":"Association between tumor mutation burden (TMB) and outcomes of cancer patients treated with PD-1\/PD-L1 inhibitions: a meta-analysis","volume":"10","author":"Zhu","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.surg.2020.05.039_bib21","doi-asserted-by":"crossref","first-page":"6193","DOI":"10.1210\/jc.2019-00600","article-title":"Nivolumab in metastatic adrenocortical carcinoma: Results of a phase 2 trial","volume":"104","author":"Carneiro","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.surg.2020.05.039_bib22","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s40425-019-0722-x","article-title":"Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma","volume":"7","author":"Habra","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.surg.2020.05.039_bib23","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1053\/j.seminoncol.2018.06.001","article-title":"Rapid disease progression in a patient with mismatch repair-deficient and cortisol secreting adrenocortical carcinoma treated with pembrolizumab","volume":"45","author":"Casey","year":"2018","journal-title":"Semin Oncol"},{"key":"10.1016\/j.surg.2020.05.039_bib24","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.2147\/OTT.S159979","article-title":"\u03b2-Catenin-driven adrenocortical carcinoma is characterized with immune exclusion","volume":"11","author":"Liu","year":"2018","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.surg.2020.05.039_bib25","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1210\/js.2019-00305","article-title":"Response to immunotherapy in combination with mitotane in patients with metastatic adrenocortical cancer","volume":"3","author":"Head","year":"2019","journal-title":"J\u00a0Endocr Soc"}],"container-title":["Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039606020303512?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039606020303512?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T10:56:04Z","timestamp":1758538564000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039606020303512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0039606020303512"],"URL":"https:\/\/doi.org\/10.1016\/j.surg.2020.05.039","relation":{},"ISSN":["0039-6060"],"issn-type":[{"value":"0039-6060","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular genomic profiling of adrenocortical cancers in clinical practice","name":"articletitle","label":"Article Title"},{"value":"Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.surg.2020.05.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}